Good potential news for lung cancer treatment if the product is successfully brought to the market place...BD
Helix BioPharma Corp. has announced the issuance of its second DOS47 patent (U.S. Patent # 7,264,800) from the United States Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications.
TCAT is designed to offer a means of deriving a therapeutic pharmacologic al effect by acting upon a naturally occurring substance in the body. The technology is based on the principle of using an enzyme to catalyse the metabolism (catabolism) of an endogenous substrate molecule in order to yield metabolites of therapeutic benefit.
L-DOS47 is unlike any cancer therapeutic on the market today. Its pharmacological effect is based on a biochemical enzyme reaction, whereby the urease compound acts repeatedly on the urea compound in a continuous manner. By doing so, L-DOS47 is expected to have the potential for unprecedented lung cancer fighting abilities, by acting in a repetitive manner to kill lung cancer cells.